The Bradykinin System Contributes to the Regulation of Prostaglandin-Endoperoxide Synthase 2 Expression in Human Amnion Fibroblasts: Implications for Term and Preterm Birth.
PGE2
bradykinin
chorioamnionitis
cyclooxygenase-2
fetal membranes
inflammation
parturition
preterm birth
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
02
2022
accepted:
08
04
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Bradykinin (BK) and its biologically active metabolite des-Arg9 bradykinin (DABK) play a pivotal role in inflammation. Since chorioamnionitis is the leading cause of preterm birth and prostaglandin E2 (PGE2) derived from the amnion is key to labor initiation, we investigated if bradykinin peptides are part of the regulatory network of PGE2 synthesis in human amnion at parturition. Human amnion tissue was obtained from term and preterm birth for the study of the changes of the bradykinin system at parturition. Cultured primary human amnion fibroblasts, the major source of PGE2, were used to study the effects of bradykinin peptides on PTGS2 expression and PGE2 production as well as the effects of infection mediators on bradykinin receptors. Bradykinin peptides and their receptors BDKRB1 and BDKRB2 were present in human amnion, and their abundance increased in term and preterm labor. However, transcripts of the genes encoding the bradykinin precursor and its proteolytic cleavage enzymes were hardly detectable in human amnion despite the increased abundance of bradykinin peptides in term and preterm labor, suggesting that there is an alternative source of bradykinin peptides for human amnion and their actions are enhanced in human amnion at parturition. This study demonstrated for the first time that the human amnion is a target tissue of bradykinin peptides and the bradykinin system may be part of the regulatory network of PTGS2 expression and PGE2 production in human amnion fibroblasts at both term and preterm birth, which may be enhanced by infection.
Sections du résumé
Background
Bradykinin (BK) and its biologically active metabolite des-Arg9 bradykinin (DABK) play a pivotal role in inflammation. Since chorioamnionitis is the leading cause of preterm birth and prostaglandin E2 (PGE2) derived from the amnion is key to labor initiation, we investigated if bradykinin peptides are part of the regulatory network of PGE2 synthesis in human amnion at parturition.
Methods
Human amnion tissue was obtained from term and preterm birth for the study of the changes of the bradykinin system at parturition. Cultured primary human amnion fibroblasts, the major source of PGE2, were used to study the effects of bradykinin peptides on PTGS2 expression and PGE2 production as well as the effects of infection mediators on bradykinin receptors.
Results
Bradykinin peptides and their receptors BDKRB1 and BDKRB2 were present in human amnion, and their abundance increased in term and preterm labor. However, transcripts of the genes encoding the bradykinin precursor and its proteolytic cleavage enzymes were hardly detectable in human amnion despite the increased abundance of bradykinin peptides in term and preterm labor, suggesting that there is an alternative source of bradykinin peptides for human amnion and their actions are enhanced in human amnion at parturition.
Conclusions
This study demonstrated for the first time that the human amnion is a target tissue of bradykinin peptides and the bradykinin system may be part of the regulatory network of PTGS2 expression and PGE2 production in human amnion fibroblasts at both term and preterm birth, which may be enhanced by infection.
Identifiants
pubmed: 35634493
doi: 10.3389/fendo.2022.873727
pmc: PMC9130483
doi:
Substances chimiques
Lipopolysaccharides
0
Transcription Factors
0
Cyclooxygenase 2
EC 1.14.99.1
Dinoprostone
K7Q1JQR04M
Bradykinin
S8TIM42R2W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
873727Informations de copyright
Copyright © 2022 Ni, Wang, Liu, Lin, Zhang, Lei, Ling, Pan, Zhu, Li, Duan, Liu and Sun.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Pharmacol. 1997 Dec;122(8):1585-92
pubmed: 9422802
Endocrinology. 2012 Oct;153(10):4938-45
pubmed: 22919060
Am J Obstet Gynecol. 1996 Dec;175(6):1668-74
pubmed: 8987958
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31
pubmed: 28935640
Sci Signal. 2015 Oct 27;8(400):ra106
pubmed: 26508788
Pharmacol Res. 1997 Jun;35(6):537-40
pubmed: 9356205
J Clin Endocrinol Metab. 2003 Nov;88(11):5564-71
pubmed: 14602805
Br J Obstet Gynaecol. 1997 Apr;104(4):495-9
pubmed: 9141588
FASEB J. 2019 Jul;33(7):8148-8160
pubmed: 30917001
Gene. 2016 May 25;583(1):48-57
pubmed: 26945629
J Cell Biochem. 2010 May;110(1):141-50
pubmed: 20411591
Immunopharmacology. 1996 Jun;33(1-3):164-6
pubmed: 8856140
Am J Obstet Gynecol. 1981 Feb 15;139(4):373-81
pubmed: 6781352
Immunol Rev. 2009 Mar;228(1):212-24
pubmed: 19290930
Endocr Rev. 2018 Jun 1;39(3):241-260
pubmed: 29385440
Hippokratia. 2007 Jul;11(3):124-8
pubmed: 19582206
Mol Cell Endocrinol. 2015 May 15;407:57-66
pubmed: 25766502
Br J Pharmacol. 1993 Nov;110(3):1227-31
pubmed: 8298813
Kidney Int. 2006 Sep;70(5):901-9
pubmed: 16820791
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):665-70
pubmed: 14704277
Eur J Pharmacol. 2018 May 15;827:181-188
pubmed: 29548973
Chem Immunol Allergy. 2014;100:140-7
pubmed: 24925394
Elife. 2020 Jul 07;9:
pubmed: 32633718
Am J Hypertens. 2021 Apr 20;34(4):304-306
pubmed: 33877321
Clin Exp Immunol. 2019 Jul;197(1):95-110
pubmed: 30793298
Bibl Haematol. 1983;(49):239-46
pubmed: 6421272
BJOG. 2006 Dec;113 Suppl 3:17-42
pubmed: 17206962
Biochim Biophys Acta. 2000 Jan 10;1495(1):69-77
pubmed: 10634933
Biol Reprod. 1991 Feb;44(2):269-74
pubmed: 2009329
J Immunol. 2004 Oct 15;173(8):5219-28
pubmed: 15470067
Am J Physiol. 1997 Dec;273(6):L1132-40
pubmed: 9435567
Am J Physiol Lung Cell Mol Physiol. 2002 Sep;283(3):L612-8
pubmed: 12169581
Pharmacol Rev. 2005 Mar;57(1):27-77
pubmed: 15734727
Mol Hum Reprod. 2019 Jul 1;25(7):408-422
pubmed: 31211832
Prostaglandins. 1992 Sep;44(3):237-44
pubmed: 1410528
Placenta. 2003 Apr;24 Suppl A:S33-46
pubmed: 12842412
Front Immunol. 2020 Jun 09;11:1038
pubmed: 32582166
J Immunol. 2006 Jan 1;176(1):580-8
pubmed: 16365453
Clin Transl Med. 2021 Jun;11(6):e416
pubmed: 34185432
J Reprod Fertil. 1988 Mar;82(2):617-25
pubmed: 3361497
Sci Rep. 2017 Apr 6;7(1):693
pubmed: 28386088
FEBS Lett. 2004 Feb 27;560(1-3):30-4
pubmed: 14987993
Biochim Biophys Acta. 1988 Mar 17;964(3):329-39
pubmed: 3126819
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 23125017
Placenta. 2019 Apr;79:40-45
pubmed: 30454905
Adv Exp Med Biol. 1986;198 Pt A:167-72
pubmed: 3101410
J Allergy Clin Immunol. 2002 Feb;109(2):195-209
pubmed: 11842287
Placenta. 2021 Jan 15;104:208-219
pubmed: 33429118
FASEB J. 2020 Jun;34(6):7265-7269
pubmed: 32359101
Pharmacol Rev. 1992 Mar;44(1):1-80
pubmed: 1313585
Iran J Immunol. 2021 Mar;18(1):93-94
pubmed: 33787518
Cell Commun Signal. 2020 Nov 23;18(1):185
pubmed: 33228717
Allergy. 2011 Nov;66(11):1397-406
pubmed: 21859431